Skip to main content
Strategic Partners A/S logo

Strategic Partners A/S — Investor Relations & Filings

Ticker · STRAP ISIN · DK0062502894 LEI · 54930025OZD2GGSQ7L42 CO Financial and insurance activities
Open in API
Filings indexed 501 across all filing types
Latest filing 2020-12-27 Legal Proceedings Report
Country DK Denmark
Listing CO STRAP

About Strategic Partners A/S

https://www.strategic-partners.dk/

Strategic Partners A/S is an investment company that engages in strategic partnerships with businesses that have significant potential. The company's strategy involves taking an active ownership role to create value through its competencies. In addition to its primary focus, the firm may also invest in other equity interests and properties to generate returns. Formerly known as Orphazyme A/S, the company sold its biotechnology activities in May 2022. A new board and management team was appointed in May 2023, and the company officially adopted its new strategy, purpose, and name in October 2024.

Recent filings

Filing Released Lang Actions
Legal Proceedings Report 2020
Legal Proceedings Report Classification · 99% confidence The document is explicitly titled "Company announcement Orphazyme A/S No. 73/2020" and discusses a "regulatory update on arimoclomol for NPC," specifically mentioning the FDA extending the review period for the New Drug Application (NDA) and setting a new PDUFA target action date. This content is a direct communication to the market regarding regulatory progress and key operational updates, rather than a comprehensive annual report (10-K), a quarterly report (IR), or a formal transcript (CT). Since it is a specific announcement about regulatory status and company progress, it fits best under the general category of Regulatory Filings (RNS) as a broad announcement, or potentially an Earnings Release (ER) if it were tied to a specific reporting period's results, but here it is focused purely on regulatory action. Given the nature of the update (FDA action on an NDA), it is a material event announcement. Since there is no specific category for 'Regulatory Update' outside of the general 'RNS', and it is not a formal financial report, RNS is the most appropriate fallback for a material, non-financial-statement-focused announcement. However, because it is a company announcement providing key operational/regulatory news, it is often classified as a general regulatory filing or announcement.
2020-12-27 English
Kim Stratton, CEO, resigns from Orphazyme
Board/Management Information Classification · 100% confidence The document is a company announcement regarding the resignation of the CEO, Kim Stratton, and the appointment of the Chairman to assist the executive team. This falls under the category of changes in senior management.
2020-12-10 English
Board/Management Information 2020
Board/Management Information Classification · 98% confidence The document is titled 'Kim Stratton, CEO, resigns from Orphazyme' and is explicitly labeled as a 'Company announcement' containing 'Inside information'. It details a change in senior management (CEO resignation and temporary replacement). This directly corresponds to the definition of Board/Management Information (MANG). Although it is a regulatory announcement, the specific content points strongly to MANG over the general 'RNS' fallback.
2020-12-10 English
Orphazyme submits European Marketing Authorisation Application for arimoclomol for treatment of Niemann-Pick disease Type C
Regulatory Filings Classification · 95% confidence The document is a company announcement from Orphazyme A/S regarding the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA). It is a standard corporate press release detailing a regulatory milestone. Since it does not fit into specific categories like financial reports, board changes, or shareholder voting, and serves as a general regulatory update/announcement, it is classified as a Regulatory Filing (RNS).
2020-11-09 English
Regulatory Filings 2020
Regulatory Filings Classification · 98% confidence The document is a formal announcement from Orphazyme A/S, dated November 9, 2020, detailing a significant regulatory event: the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for their drug arimoclomol. This is a specific corporate update regarding regulatory progress, not a comprehensive annual report (10-K), an earnings release (ER), or a transcript (CT). It is an announcement concerning regulatory filings and progress, but it is not a general regulatory filing (RNS) or a report publication announcement (RPA) in the sense of merely announcing the availability of a pre-existing report. Since the core content is about a specific regulatory submission (MAA) and related progress (FDA NDA review), it falls under the category of general corporate news related to operations and regulatory milestones. Given the options, this type of announcement, which details specific regulatory actions and pipeline progress, is best classified as a general Regulatory Filing (RNS) as it is a formal communication to the market about a regulatory event, or potentially a Legal Proceedings Report (LTR) if the focus was on litigation, but here it is clearly regulatory submission news. Since RNS is the general regulatory announcement fallback and this is a specific regulatory submission announcement, RNS is the most appropriate fit among the provided codes for a non-standard, specific regulatory update that isn't a core financial report.
2020-11-09 English
Share Issue/Capital Change 2020
Share Issue/Capital Change Classification · 99% confidence The document is a 'Company announcement' from Orphazyme A/S dated November 3, 2020, explicitly stating the 'End of stabilization period' following a Global Offering. It references previous announcements regarding the stabilization period and includes detailed tables showing stabilization transactions undertaken by the stabilizing manager (BofA Securities, Inc.) concerning the American Depositary Shares (ADSs) and Ordinary Shares. This type of announcement, detailing the conclusion of market stabilization activities related to an offering, is a specific corporate action disclosure. It is not a full financial report (10-K, IR), an earnings release (ER), or a general proxy/shareholder vote document. It relates most closely to capital market activities, specifically post-offering stabilization. Among the provided codes, 'CAP' (Capital/Financing Update) is the most appropriate fit as stabilization is intrinsically linked to the financing/offering process. It is not a general regulatory filing (RNS) because it addresses a very specific, defined corporate finance event.
2020-11-03 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.